Valneva SE (VALN) Non-Current Assets (2020 - 2026)
Valneva SE (VALN) posted quarterly Non-Current Assets of $194.1 million for Q1 2026, down 12.61% year-on-year from $222.1 million in Q1 2025, and down 3.25% on a QoQ basis from $200.6 million in Q4 2025.
Valneva SE (VALN) Non-Current Assets (2020 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Non-Current Assets for 7 consecutive years, with $194.1 million the latest figure, recorded in Q1 2026.
- Quarterly Non-Current Assets fell 12.61% year-over-year to $194.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $813.3 million (down 11.4% YoY) and the FY2025 annual result came in at $200.6 million, down 12.3% from the prior year.
- Non-Current Assets declined to $194.1 million in Q1 2026 per VALN's latest filing, from $200.6 million in the prior quarter.
- Over the last five years, Non-Current Assets for VALN reached as high as $264.8 million in Q1 2022 and fell as low as $194.1 million in Q1 2026.
- A 5-year average of $226.9 million and a median of $224.7 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets climbed 6.56% — and 2025, when it fell 15.54%.
- Year by year, Non-Current Assets stood at $223.8 million in 2022, then advanced by 0.28% to $224.4 million in 2023, then increased by 1.92% to $228.8 million in 2024, then slipped by 12.3% to $200.6 million in 2025, then fell by 3.25% to $194.1 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $194.1 million, $200.6 million, and $204.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | 194.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 194.11 Mn |
| Dec 31, 2025 | 200.62 Mn |
| Sep 30, 2025 | 204.72 Mn |
| Jun 30, 2025 | 213.83 Mn |
| Mar 31, 2025 | 222.12 Mn |
| Dec 31, 2024 | 228.75 Mn |
| Sep 30, 2024 | 242.38 Mn |
| Jun 30, 2024 | 224.65 Mn |
| Mar 31, 2024 | 223.71 Mn |
| Dec 31, 2023 | 224.45 Mn |
| Sep 30, 2023 | 227.46 Mn |
| Jun 30, 2023 | 228.83 Mn |
| Mar 31, 2023 | 228.35 Mn |
| Dec 31, 2022 | 223.82 Mn |
| Sep 30, 2022 | 252.11 Mn |
| Jun 30, 2022 | 251.86 Mn |
| Mar 31, 2022 | 264.79 Mn |
| Dec 31, 2021 | 263.46 Mn |
| Dec 31, 2020 | 160.15 Mn |